Schrödinger Appoints Professor Brian Shoichet to Scientific Advisory Board

NEW YORK–(BUSINESS WIRE)–Schrödinger
today announced the appointment of Professor of Chemistry Brian
Shoichet, Ph.D., a widely published thought leader in the field of
computational drug discovery, to its scientific
advisory board (SAB). Schrödinger is a privately held company
revolutionizing drug discovery and materials design through advanced
molecular simulations.

“I am thrilled to join the exceptional team at Schrödinger in support of
our shared mission to open new possibilities for drug discovery by
continuing to advance the field of computational modeling,” said
Professor Shoichet.

Professor Shoichet brings over two decades of extensive experience in
drug discovery and design. He currently serves in the Department of
Pharmaceutical Chemistry at the University of California, San Francisco,
where his lab combines computational modeling with detailed experimental
testing and applies the resulting methods to new chemotype discovery.
Professor Shoichet has published scores of papers in top scientific
journals.

“We are delighted to welcome Brian to the advisory board,” said Ramy
Farid, Ph.D., Schrödinger’s CEO. “We’re excited to collaborate with a
leading scientist of Brian’s caliber to continue to expand our
platform’s capabilities.”

“I am specifically interested in focusing on how FEP+ can improve
workflows during early compound optimization for hits selected from
large library docking screens,” Professor Shoichet added.

Professor Shoichet joins a team of leading biophysicists, chemists, and
bioinformaticians on Schrödinger’s SAB, which is chaired by Professor
Richard Friesner, director of the Columbia Center for Biomolecular
Simulation and a co-founder of Schrödinger.

About Schrödinger
Schrödinger has a substantial and growing
global business, licensing its industry-leading computational platform
to pharmaceutical, biotechnology, chemical, and electronics companies to
accelerate R&D in both drug discovery and materials design. Schrödinger
has built a robust pipeline of therapeutic assets, held both internally
and in partnerships, and has co-founded leading biotech companies,
including Nimbus Therapeutics and Morphic Therapeutic. Schrödinger’s
significant and ongoing investment in basic research continues to drive
advances in its computational platform. Founded in 1990, Schrödinger has
nearly 400 employees in its New York City headquarters and around the
world. Visit schrodinger.com
for more information.

Contacts

Stephanie Simon
[email protected]
617-581-9333